ABPI: International comparisons in medicines spending and the link to competitiveness
Kim Assender, the Association of the British Pharmaceutical Industries’ (ABPI) director of commercial policy and analysis, explores the question: 'What is the “right” level of medicines spending to deliver optimal patient outcomes while sustaining our health system and fostering economic growth?' Drawing on a new report from IQVIA Global Market Insights, ‘Drug Expenditure Dynamics 2000–2022’.
The IQVIA Institute report shows that while drug spending across 12 major markets averages around 15% of total healthcare expenditure, the UK remains a consistent outlier at just 9%, the lowest among the countries studied.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze